Rezolute Inc Asset Resilience Ratio
Rezolute Inc asset resilience ratio. Rezolute Inc (RZLT) has an Asset Resilience Ratio of 86.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RZLT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Rezolute Inc (2015–2025)
Asset resilience ratio of Rezolute Inc from 2015 to 2025. This chart shows how Rezolute Inc's Asset Resilience Ratio has changed over time. Read Rezolute Inc (RZLT) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Rezolute Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Rezolute Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $109.03 Million | 86.91% |
| Total Liquid Assets | $109.03 Million | 86.91% |
Asset Resilience Insights
- Very High Liquidity: Rezolute Inc maintains exceptional liquid asset reserves at 86.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rezolute Inc Industry Peers by Asset Resilience Ratio
Compare Rezolute Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Rezolute Inc Asset Resilience Ratio by Year (2015–2025)
Rezolute Inc asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Rezolute Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 42.03% | $73.75 Million | $175.49 Million | -0.52pp |
| 2024-06-30 | 42.55% | $56.48 Million | $132.74 Million | -26.85pp |
| 2023-06-30 | 69.40% | $85.86 Million | $123.72 Million | -- |
| 2022-06-30 | 0.00% | $0.00 | $152.42 Million | -- |
| 2015-06-30 | 4.00% | $450.00K | $11.26 Million | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more